SCHEMBL4483680

SCHEMBL4483680

O=S(=O)(NN1CCCCC1)c1ccc2c(c1)C=CCO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.38
STS P08842 1/20 0.36
CYP2B6 P20813 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX12 P18054 1/20 0.33
NFKB1 P19838 1/20 0.33
CCKBR P32239 1/20 0.33
LMNA P02545 3/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
FFAR4 Q5NUL3 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739311 0.76 STS (0.43) STSCYP2B6ALDH1A1KDM4ELMNA
SCHEMBL27798617 0.73 STS (0.43) STSCYP2B6LMNARAB9APKM
SCHEMBL5336264 0.73 STS (0.50) STSCYP2B6MAPTGAAKDM4E
SCHEMBL31700562 0.73 STS (0.50) STSCYP2B6MAPTGAAKDM4E
SCHEMBL11506043 0.73 STS (0.43) STSCYP2B6ALDH1A1MAPTRAB9A
SCHEMBL8365309 0.72 GAA (0.62) ALDH1A1GAALMNARAB9ASMN1; SMN2
SCHEMBL7131545 0.67 PHGDH (0.49) PHGDHALDH1A1MAPTGAAKDM4E
SCHEMBL9189792 0.67 PHGDH (0.49) PHGDHALDH1A1MAPTGAAKDM4E
SCHEMBL6801446 0.67 MAPT (0.55) PHGDHALDH1A1MAPTGAAKDM4E
SCHEMBL3799154 0.66 LMNA (0.53) PHGDHALDH1A1MAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534801-B2 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-05-19 US disclosed
US-7534801-B2 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-05-19 US disclosed
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-05-19 US disclosed
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-05-19 US disclosed
WO-2005037830-A1 PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, TPH1 PHGDH 2193/4885STS 1277/4885CYP2B6 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.